Skip to main content
TipRanks
Go Ultimate75% OFF

ProMIS Neurosciences (23J) Q3 2026 Earnings Report

3 Followers

DE:23J Q3 2026 EPS Results

Actual EPS
-EUR 0.81
Consensus EPS
-EUR 1.16
Beat/Miss
Beat by +EUR 0.35
One Year Ago EPS
-EUR 5.47

DE:23J Q3 2026 Revenue Results

Actual Revenue
EUR 0
Expected Revenue
EUR 0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
DE:23J Upcoming Earnings

ProMIS Neurosciences's next earnings date is estimated for March 31, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:23J Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-17.24%|
Earnings Call Sentiment|Positive

The call was strongly optimistic, supported by encouraging interim safety and biomarker findings, a clear development timeline, cash funding through 2027, and active preparation for regulatory and late-stage development. However, the central efficacy readout remains pending, the interim data are blinded and not definitive, the study is relatively small, and several regulatory and formulation decisions remain unresolved.

Company Guidance

Promise said all patient visits are expected to conclude this quarter, with unblinded 12 months top line data from PRECISE AD remaining on track for the first quarter of 2027; the 140-patient study is evaluating 12 months of treatment, and management said a result showing safety approaching or close to background or placebo rates, especially around ARIA-E, with efficacy roughly 15 to 20 percent on either iADRS or CDR Sum of Boxes, supported by directional trends in key biomarkers, would be a significant win, while any benefit above 20 percent would be total upside. The company ended Q3 with approximately $44.1 million in cash, which it expects to fund operations through 2027, intends to request a meeting with FDA after the full set of data is analyzed, is developing a subcutaneous formulation, and could envision beginning a potential registration study towards the end of 2027, subject to FDA feedback.

  • PRECISE AD Trial Nears CompletionAll patient visits in the Phase 1b PRECISE AD trial are expected to conclude in the third quarter, and unblinded 12-month top-line data remain on track for the first quarter of 2027.
  • PMN310 Demonstrates Selective Oligomer Targeting in Preclinical TestingIn head-to-head preclinical studies, PMN310 was the only antibody tested that bound toxic amyloid-beta oligomers while avoiding monomers, fibrils, and plaque.
  • PMN310 Design Combines Neutralization and ClearancePMN310 uses an IgG1 backbone, like the two approved antibodies, to engage microglia and actively clear toxic oligomers from the brain while also neutralizing them.
  • Encouraging Interim ARIA Safety ProfileAt the six-month interim analysis, there were 0 cases of ARIA-E across any APOE genotype among the safety-evaluable population. ARIA-H occurred at a rate of 4.4%, with all cases mild and asymptomatic and described as being in line with placebo rates.
  • No Drug-Related Discontinuations or Treatment-Related Serious Adverse EventsThe six-month interim analysis reported no drug-related discontinuations and no treatment-related serious adverse events.
  • Interim Biomarker Changes Support Target EngagementBlinded, pooled observations showed plasma p-tau217 decreased approximately 15% from baseline and CSF MTBR-tau243 decreased approximately 13% from baseline. Management emphasized that these observations were not a determination of efficacy but were consistent with target engagement.
  • Comprehensive Phase 1b Study DesignPRECISE AD is a 12-month, 140-patient study with 3-to-1 randomization to active treatment versus placebo and includes biomarker, safety, clinical outcome, and oligomer mechanism-of-action endpoints. The safety and biomarker interim analysis included 136 safety-evaluable patients.
  • Defined Criteria for a Successful Top-Line ReadoutManagement said it will evaluate safety, clinical efficacy, biomarkers, and mechanism of action. The desired profile includes ARIA and drug-related adverse-event rates approaching or comparable to placebo, directional slowing of decline on either iADRS or CDR Sum of Boxes versus placebo similar to approved therapies at 12 months, biomarker trends consistent with oligomer selectivity, and direct reductions in oligomer levels.
  • Direct Oligomer Measurement Assay Being ImplementedThe company has developed an assay that measures absolute concentrations of amyloid-beta oligomers in cerebrospinal fluid with subpicomolar sensitivity, rather than inferring oligomer levels from antibody saturation. The assay is being implemented in PRECISE AD to measure pre- and post-treatment oligomer levels.
  • Preclinical Evidence of Functional EffectsIn transgenic mice, PMN310 treatment preserved memory acquisition and retrieval and reduced inflammatory cytokines in the brain compared with untreated animals.
  • Consistent Target Epitope Across Alzheimer’s Disease Brain SamplesManagement stated that the conformational epitope recognized by PMN310 was consistent across hundreds of Alzheimer’s disease brains tested, and that PMN310 removed the bulk of oligomer material from low-molecular-weight brain homogenate fractions enriched for oligomers.
  • Regulatory and Late-Stage Planning UnderwayWith Fast Track designation already granted, the company intends to request an FDA meeting after the full PRECISE AD dataset is analyzed. It is also preparing for a potential registration study that could begin toward the end of 2027, subject to FDA feedback.
  • Subcutaneous Formulation Development ProgressingThe company is developing a subcutaneous formulation of PMN310. Early studies were described as encouraging, including work on viscosity, injection volume, and patient manageability, and the company intends to evaluate a subcutaneous arm in a future registration study without delaying the intravenous formulation.
  • Strengthened Leadership TeamDr. Ivana Rubino joined as chief commercial officer. She brings more than 15 years of global neuroscience and Alzheimer’s leadership from senior roles at Biogen and Roche and is expected to help shape regulatory, late-stage development, and commercial strategy.
  • Cash Runway Extends Through 2027The company ended the third quarter with approximately $44.1 million in cash and expects that balance to fund operations through 2027, beyond the PRECISE AD readout.
  • Research and Development Expenses DeclinedThird-quarter research and development expenses were approximately $6.7 million, down 32% from $9.8 million a year earlier, primarily due to a $3.6 million reduction in direct PMN310 costs as PRECISE AD moved toward completion. This was partially offset by increased activity in the ALS and pipeline programs.
  • Improved Quarterly and Year-to-Date Net LossThird-quarter net loss was $8.2 million, or $0.89 per share, compared with $11.6 million, or $5.93 per share, a year earlier. For the first nine months, net loss was approximately $28.1 million, or $3.39 per share, versus $29.0 million, or $19.58 per share, in 2025.
  • Stable General and Administrative Expenses and Higher Interest IncomeThird-quarter general and administrative expenses were approximately $1.9 million, roughly flat with $2.0 million a year earlier. Other income increased to approximately $500,000 from $200,000 due to higher interest income.
  • Broader Selective Antibody PipelineManagement stated that the company has a pipeline of selective antibodies for other serious neurodegenerative diseases with high unmet medical need, including ALS, Parkinson’s disease, and dementia with Lewy bodies.
  • Potential to Reduce MRI Monitoring BurdenThe company’s stated goal is to reduce ARIA incidence and thereby reduce repeated MRI monitoring. Management noted that FDA precedent exists for reducing MRI requirements when supported by appropriate safety data, while emphasizing that the eventual schedule would require agency discussion.

DE:23J Earnings History

DE:23J earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 31, 20272026 (Q4)-0.96--3.75――
Nov 12, 20262026 (Q3)-1.16-0.81-5.4785.17% (+4.66)
Aug 13, 20262026 (Q2)-1.26-1.17-6.6182.34% (+5.44)
May 12, 20262026 (Q1)-0.97-1.15-4.7976.00% (+3.64)
Mar 25, 20262025 (Q4)-4.25-3.752.73-237.00% (-6.48)
Nov 12, 20252025 (Q3)-6.61-5.477.06-177.42% (-12.53)
Aug 13, 20252025 (Q2)-3.96-6.61-2.96-123.08% (-3.65)
May 12, 20252025 (Q1)―--0.17―
Mar 31, 20252024 (Q4)-2.73-4.79-4.33-10.53% (-0.46)
Nov 14, 20242024 (Q3)-1.567.06-4.33263.16% (+11.39)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed